Erisyon
2 known investors
Erisyon develops a single-molecule protein sequencer using its Fluorosequencing technology, applying next-generation DNA sequencing approaches to proteomics. The platform is aimed at protein analysis and disease detection for biological research and medical applications.
Founder mafia
2 people who came through Erisyon went on to found or lead other companies.
Investors · 2
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $216.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $247.9K |
| National Science Foundation | Phase ISTTR | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Erisyon do?
- Erisyon develops a single-molecule protein sequencer using its Fluorosequencing technology, applying next-generation DNA sequencing approaches to proteomics. The platform is aimed at protein analysis and disease detection for biological research and medical applications.
- Who are Erisyon's investors?
- Erisyon's investors include Catalio Capital Management, LP, Foothill Ventures.